Shivom

Shivom operates as a global genomics and precision medicine data ecosystem, leveraging blockchain technology to create a marketplace for genomic data. Founded in 2017 by a team including Dr. Axel Schumacher, Gourish Singla, Sally Eaves, Per Lind, and Akash Gaurav, the company aims to address the challenges of data privacy and ownership in the healthcare and genomics sectors. Dr. Schumacher, the CEO, brings over two decades of experience in genomics and biomarker discovery, while Gourish Singla has a background in investment banking and crypto financial markets. This combination of scientific expertise and financial acumen underpins the company's strategic direction.

The core of Shivom's business is a platform that allows individuals to have their genomes sequenced, securely store the data, and maintain full ownership and control over it. Utilizing blockchain and smart contracts, the platform ensures that data owners can grant fine-grained, permissioned access to third parties like pharmaceutical companies, research organizations, and patient-support groups. This model empowers individuals to monetize their anonymized genetic data by selling access rights for research purposes, thereby participating directly in the advancement of medicine. Revenue is generated through the sale of OmiX tokens, which are required for all transactions on the platform, and from the sale of gene-sequencing kits. The company also plans to establish a not-for-profit R&D organization to foster open innovation, particularly for developing therapeutics for low-income populations.

Shivom's platform functions as an open web-marketplace where partners can develop and offer their own applications and services, such as genomic data analytics and personalized medicine tools. By combining genomic DNA sequencing, artificial intelligence, and cryptography, the company is building a comprehensive genomic and health data hub. This ecosystem is designed to accelerate drug discovery, improve clinical trials, and enable the development of precision medicine tailored to an individual's unique genetic makeup. A significant development was the launch of the world's first NFT marketplace for genomic data, which adds another layer of verifiable ownership and control for data donors. Shivom has engaged in several strategic partnerships, including a collaboration with the Indian state of Andhra Pradesh to sequence its population and with Genetic Technologies to advance cancer risk prediction.

Keywords: genomic data, precision medicine, blockchain healthcare, data monetization, DNA sequencing, OmiX token, genomic marketplace, personalized medicine, data ownership, smart contracts, bioinformatics, health-tech, Axel Schumacher, Gourish Singla, clinical research, drug discovery, genetic testing, data privacy, NFT, genomics ecosystem